c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: How novel, how accurate, and how significant?

Breast Cancer Research

Volumn 5, Issue 4, 2003, Pages 188-191

  Schmitt, Fernando C ^a,b   Reis Filho, Jorge S ^c,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

c erbB 2; c myc; her 2 neu; Oncogene; Polymerase chain reaction; Prognosis

Indexed keywords

BETA GLOBIN; DNA FRAGMENT; MANGANESE SUPEROXIDE DISMUTASE; ONCOPROTEIN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DATA ANALYSIS; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; ONCOGENE C MYC; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0038724936     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr606     Document Type: Article

References (25)

1. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003, 5:R30-R36.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Sahin AA: Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 2000, 7:158-166.
4. Hayes DF, Thor AD: c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002, 29:231-245.
5. Masood S, Bui MM: Prognostic and predictive value of HER2/ neu oncogene in breast cancer. Microsc Res Tech 2002, 59: 102-108.
6. Liao DJ, Dickson RB: c-Myc in breast cancer. Endocr Relat Cancer 2000, 7:143-164.
7. Deming SL, Nass SJ, Dickson RB, Trock BJ: C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000, 83:1688-1695.
8. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000, 60:1077-1083.
9. Bartlett J, Mallon E, Cooke T: The clinical evaluation of HER-2 status: which test to use? J Pathol 2003, 199:411-417.
10. van de Vijver M: Emerging technologies for HER2 testing. Oncology 2002, 63 (Suppl 1):33-38.
11. Brandt B, Vogt U, Harms F, Bosse U, Zanker KS, Assmann G: Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene 1995, 159:29-34.
12. Beckmann A, Vogt U, Huda N, Zanker KS, Brandt BH: Direct-double-differential PCR for gene dosage quantification of c-myc. Clin Chem 1999, 45:141-143.
13. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H: Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002, 82:1419-1426.
14. Armour JAL, Barton DE, Cockburn DJ, Taylor GR: The detection of large deletions or duplications in genomic DNA. Hum Mutat 2002, 20:325-337.
15. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H: Detection of gene amplification in intraductal and infiltrating breast cancer by laser-assisted microdissection and quantitative real-time PCR. Pathobiology 2000, 68:173-179.
16. Fehm T, Morrison L, Saboorian H, Hynan L, Tucker T, Uhr J: Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors. Breast Cancer Res Treat 2002, 75: 227-239.
17. Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W: Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999, 189:521-526.
18. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ: Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001, 81:1545-1551.
19. Janocko LE, Brown KA, Smith CA, Gu LP, Pollice AA, Singh SG, Julian T, Wolmark N, Sweeney L, Silverman JF, Shackney SE: Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 2001, 46:136-149.
20. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM: Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001, 193: 433-441.
21. Lynch J, Pattekar R, Barnes DM, Hanby AM, Camplejohn RS, Ryder K, Gillett CE: Mitotic counts provide additional prognostic information in grade II mammary carcinoma. J Pathol 2002, 196:275-279.
22. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D: Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999, 59:1433-1436.
23. Schmitt FC: Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 1995, 31A:2049-2052.
24. Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ: Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001, 14:1030-1035.
25. Schmitt FC, Reis Filho JS: Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? Breast 2002, 11:463-465.